To the Editor.
—In the February issue of the Archives, an editorial by Krick and Remington (p 344) critically reviews the current status of flucytosine (Ancobon) as a therapeutic agent, mainly in cryptococcal and Candida infections. The comments of the editorialists are made in connection with our clinical experience with flucytosine published in the same issue of the Archives (p 231) and our interpretation of the results of similar studies that had appeared in the literature.Because several aspects of our study are interpreted in the editorial in a manner that is at variance with our interpretation, a clarification is needed.With regard to the combined use of amphotericin B (fungizone) and flucytosine, the editorialists refer to the demonstration of in vitro synergism between these two drugs for a small number of isolates of Cryptococcus neoformans and Candida. The possibility of synergism was the justification of our use of combined
Harder EJ, Hermans PE. Treatment of Fungal Infections. Arch Intern Med. 1975;135(9):1269–1271. doi:10.1001/archinte.1975.00330090141022
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: